Benign Prostatic Hyperplasia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Eli Lilly and Company, Sophiris Bio Corp, Bayer, Warner Chilcott, Materia Medica Holding, Ausio

DelveInsight's "Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic Hyperplasia Market Forecast https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Benign Prostatic Hyperplasia Market Report:
• The Benign Prostatic Hyperplasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to a study by Boyle et al. (n.d.), up to 60% of men over 60 may have hypertension, and 50% of men over 60 may have symptoms consistent with BPH
• On February 26, 2021, Medi Tale Ltd., an Israeli producer of non-surgical Benign Prostatic Hyperplasia Devices, was purchased by Olympus Corporation. Olympus will become the market leader as a result of this transaction, which will enable it to diversify its product offering
• On January 27, 2021, Positive clinical trial results for the XFLO minimally invasive Benign Prostatic Hyperplasia therapy device had been reported by Medeon Biodesign Inc. The manufacturer of the XFLO expander device released all of the good interim findings from the EXPANDER-1 clinical study. Future product launches will have an impact on market expansion
• The most anticipated new treatments are Vibegron (Urovant Sciences) and DKF-313 (Dongkook Pharmaceutical), which are waiting for approval. In a phase II clinical trial, the novel medication AUS-131 from Ausio Pharmaceuticals was examined
• Key Benign Prostatic Hyperplasia Companies: Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharmaceuticals, LLC, Nymox Corporation, Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others
• Key Benign Prostatic Hyperplasia Therapies: DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, NX-1207, Tamsulosin, and others
• The Benign Prostatic Hyperplasia epidemiology based on gender analyzed that Benign Prostatic Hyperplasia is more common in older males as compared to those below 40 years
• The Benign Prostatic Hyperplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics.

Benign Prostatic Hyperplasia Overview
Men who have BPH, also known as benign prostatic hyperplasia, have enlarged prostates that are not malignant. Other names for benign prostatic hyperplasia are benign prostatic blockage and benign prostatic hypertrophy. The urethra is pinched and pressed against by the prostate as it grows in size. the bladder wall thickens

Get a Free sample for the Benign Prostatic Hyperplasia Market Report
https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Benign Prostatic Hyperplasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Benign Prostatic Hyperplasia Epidemiology Segmentation:
The Benign Prostatic Hyperplasia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Benign Prostatic Hyperplasia
• Prevalent Cases of Benign Prostatic Hyperplasia by severity
• Gender-specific Prevalence of Benign Prostatic Hyperplasia
• Diagnosed Cases of Episodic and Chronic Benign Prostatic Hyperplasia

Download the report to understand which factors are driving Benign Prostatic Hyperplasia epidemiology trends @ Benign Prostatic Hyperplasia Epidemiology Forecast
https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Benign Prostatic Hyperplasia Therapies and Key Companies
• DKF0313: Dongkook Pharmaceutical
• Vibegron: Urovant Sciences
• AUS-131 (S-equo): Ausio Pharmaceuticals
• GI198745: GlaxoSmithKline
• DKF-313: Dongkook Pharmaceutical Co., Ltd.
• Silodosin: RECORDATI GROUP
• ASP4901: Astellas Pharma Inc
• Tadalafil: Eli Lilly and Company
• PRX302: Sophiris Bio Corp
• Levitra (Vardenafil, BAY38-9456): Bayer
• WC3055: Warner Chilcott
• Afalaza: Materia Medica Holding
• S-equol: Ausio Pharmaceuticals, LLC
• NX-1207: Nymox Corporation
• Tamsulosin: Siami, Paul F., M.D

Discover more about therapies set to grab major Benign Prostatic Hyperplasia market share @ Benign Prostatic Hyperplasia Treatment Market
https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Benign Prostatic Hyperplasia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Benign Prostatic Hyperplasia Companies: Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, Dongkook Pharmaceutical Co., Ltd., RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharmaceuticals, LLC, Nymox Corporation, Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others
• Key Benign Prostatic Hyperplasia Therapies: DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, NX-1207, Tamsulosin, and others
• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Benign Prostatic Hyperplasia Unmet Needs, KOL's views, Analyst's views, Benign Prostatic Hyperplasia Market Access and Reimbursement

To know more about Benign Prostatic Hyperplasia companies working in the treatment market, visit @ Benign Prostatic Hyperplasia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Benign Prostatic Hyperplasia Market Report Introduction
2. Executive Summary for Benign Prostatic Hyperplasia
3. SWOT analysis of Benign Prostatic Hyperplasia
4. Benign Prostatic Hyperplasia Patient Share (%) Overview at a Glance
5. Benign Prostatic Hyperplasia Market Overview at a Glance
6. Benign Prostatic Hyperplasia Disease Background and Overview
7. Benign Prostatic Hyperplasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Benign Prostatic Hyperplasia
9. Benign Prostatic Hyperplasia Current Treatment and Medical Practices
10. Benign Prostatic Hyperplasia Unmet Needs
11. Benign Prostatic Hyperplasia Emerging Therapies
12. Benign Prostatic Hyperplasia Market Outlook
13. Country-Wise Benign Prostatic Hyperplasia Market Analysis (2019-2032)
14. Benign Prostatic Hyperplasia Market Access and Reimbursement of Therapies
15. Benign Prostatic Hyperplasia Market Drivers
16. Benign Prostatic Hyperplasia Market Barriers
17. Benign Prostatic Hyperplasia Appendix
18. Benign Prostatic Hyperplasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Benign Prostatic Hyperplasia Pipeline https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Benign Prostatic Hyperplasia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Benign Prostatic Hyperplasia market. A detailed picture of the Benign Prostatic Hyperplasia pipeline landscape is provided, which includes the disease overview and Benign Prostatic Hyperplasia treatment guidelines.
Benign Prostatic Hyperplasia Epidemiology https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Benign Prostatic Hyperplasia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Benign Prostatic Hyperplasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.